Fenfluramine for treating seizures associated with Dravet syndrome

2.1 Fenfluramine (Fintepla, Zogenix) is licensed for 'the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-seizure medicines for patients 2 years of age and older'.

2.2 Fenfluramine is taken orally. It can be used with or without stiripentol. Because of how fenfluramine is metabolised, the recommended maintenance dose after titration is 0.7 mg/kg/day (maximum 26 mg/day) for people not taking stiripentol, and 0.4 mg/kg/day for people taking stiripentol (maximum 17 mg/day). See details of the dosage schedule in the summary of product characteristics for fenfluramine.

2.3 The list price of fenfluramine is £901.44 per 60 ml bottle, £1,802.88 per 120 ml bottle and £5,408.65 per 360 ml bottle (BNF online accessed February 2022). The company has a commercial arrangement. This makes fenfluramine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.